HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
HealthEquity (HQY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$104.43 | $115.00 | $92.00 | 31.26% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for HealthEquity comes to $104.43. The forecasts range from a low of $92.00 to a high of $115.00. The average price target represents an increase of 31.26% from the last closing price of $79.56.
Analyst Price Targets (14)
Broker Rating
HealthEquity currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HQY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Guggenheim Securities | Jack D Wallace | Strong Buy | Strong Buy |
6/4/2024 | Robert W. Baird & Co. | Mark S Marcon | Strong Buy | Strong Buy |
6/4/2024 | Wells Fargo Securities | Stan Berenshteyn | Strong Buy | Strong Buy |
5/31/2024 | Raymond James | Charles G Peters | Moderate Buy | Moderate Buy |
4/4/2024 | JMP Securities | Constantine Kyriakos Davides | Not Available | Strong Buy |
3/28/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/22/2024 | Barrington Research | Alexander P Paris | Strong Buy | Strong Buy |
3/22/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
3/20/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
2/27/2024 | BTIG | David M Larsen | Strong Buy | Strong Buy |
2/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $104.43 |
LT Growth Rate | 28.00% |
Industry | Medical Services |
Industry Rank by ABR | 172 of 253 |
Current Quarter EPS Est: | 0.70 |